how is molecular testing used to select upfront therapy in patients with egfr mutations?
Published 7 years ago • 28 plays • Length 5:07Download video MP4
Download video MP3
Similar videos
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
1:04
molecular testing in egfr mutant driven nsclc
-
1:41
egfr mutations in patients with lung cancer
-
4:28
mutation testing for advanced lung cancer
-
3:36
testing and recommendations: egfr-mutated stage iv nsclc
-
1:13
identification of egfr mutations impact overall prognosis in lung cancers
-
9:30
egfr testing for nsclc
-
28:28
patient selection, therapeutic sequencing, & treatment selection in egfr mutation-positive nsclc
-
27:31
molecular testing & targeted therapy
-
4:41
upfront egfr-targeted therapy for nsclc
-
4:25
how to understand egfr t790m mutations | dana-farber cancer institute
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
4:06
afatinib in patients with uncommon egfr mutations
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
3:48
mechanisms of resistance to upfront egfr-targeted therapy
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
1:56
what targeted therapies are used for people with the egfr mutation?
-
7:07
mutation testing in nsclc
-
1:41
physician perceptions of testing practices in patients with egfr mutated nsclc